Xolair (omalizumab) is a brand-name subcutaneous injection that’s prescribed for hives, asthma, and other conditions. This article covers topics such as side effects, dosage, and how Xolair works.

The recommended Xolair dosage (subcutaneous injection) for the treatment of food allergy is 75-600 mg, once every two or four weeks. Roche has a collaboration agreement with fellow Swiss pharma ...

The approved dose is 300 mg by subcutaneous injection every four weeks. "The EU approval of Xolair in CSU is truly exciting for patients with this chronic and debilitating skin disease," said ...

The biosimilar's safety and immunogenicity profiles were found to be comparable to those of the reference product in the trial.

Xolair (omalizumab ... which is available in markets in the US and EU as a subcutaneous injection lasting a few minutes, instead of a lengthy infusion. Sandra Horning, chief medical officer ...